Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyCHRS +1.52%57 3-1 Month Momentum % is -10.56% as of Sep. 10, 2026. GuruFocus rates CHRS with a GF Score™ of 57/100 and a GF Value™ of $1.04 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,382 Biotechnology companies, Coherus Oncology ranks worse than 71.2% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-10), Coherus Oncology's 3-1 Month Momentum % is -10.56%.
The industry rank for Coherus Oncology's 3-1 Month Momentum % or its related term are showing as below:
CHRS's 3-1 Month Momentum % is ranked worse than 71.2% of 1382
companies
in the Biotechnology industry
Industry Median: 1.21
vs CHRS: -10.56
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Coherus Oncology 3-1 Month Momentum % Related Terms
CHRS vs VYGR, KROS, DTIL: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Coherus Oncology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (CHRS) has a 3-1 Month Momentum % of -10.56% as of Sep. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #984 out of 1382 companies in the Biotechnology industry, placing it in the top 71.2%.
Is Coherus Oncology's 3-1 Month Momentum % too high?
Coherus Oncology's current 3-1 Month Momentum % is -10.56%. Based on the distribution chart, Coherus Oncology ranks #984 out of 1382 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's 3-1 Month Momentum % compare to VYGR and KROS?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #984 out of 1382 companies for 3-1 Month Momentum %. This places Coherus Oncology in the lower half of its industry. The industry median 3-1 Month Momentum % is 1.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.21, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current 3-1 Month Momentum % is -10.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.04, compared to a current price of $1.34 — trading 28.8% above its estimated fair value. The current 3-1 Month Momentum % is -10.56%. Coherus Oncology's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current 3-1 Month Momentum % is -10.56% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (CHRS) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of $1.34 is trading 28.8% above its estimated GF Value™ of $1.04.
GuruFocus considers Coherus Oncology to be Modestly Overvalued.
Key valuation signals for CHRS:
3-1 Month Momentum %: -10.56%
GF Value™: $1.04 vs. price of $1.34 (28.8% above fair value)
No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
57GF Score
Get the complete analysis for CHRS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHRS has been successfully added to your 
